## Amendments to the Claims

CLAIM:

1. (Currently Amended) A compound of formula I:

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is 
$$-C(R^{4c}) = or -N = ;$$

 $R^1$  is  $C_1$ - $C_6$  alkyl, substituted  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_7$  cycloalkyl, substituted  $C_2$ - $C_7$  cycloalkyl, substituted  $C_2$ - $C_7$  cycloalkyl  $C_1$ - $C_2$  alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo,  $C_1$ - $C_2$  alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

R<sup>2</sup> is hydrogen or methyl; , C<sub>1</sub>-C<sub>3</sub>-alkyl optionally substituted with one to three fluoro substituents, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, or a group of formula II

 $R^3$  is hydrogen or  $C_1$ -  $C_3$  alkyl;

 $R^{4a}$  and  $R^{4b}$  are independently hydrogen, halo, or  $C_4$ - $C_4$  alkyl optionally substituted with one to three fluoro substituents;

When X is  $-C(R^{4c})$ =,  $R^{4c}$  is hydrogen, halo, or  $C_1$ - $C_4$  alkyl optionally substituted with one to three fluoro substituents;

 $R^5$  is hydrogen or  $C_4$ - $C_3$ -alkyl optionally substituted with one to three fluoro substituents; and

 $R^6$  is hydrogen or  $C_4$ - $C_3$ -alkyl optionally substituted with one to three fluoro substituents, provided that  $R^6$ -may be  $C_4$ - $C_3$ -alkyl only when  $R^5$  is other than hydrogen;

 $R^2$  is hydrogen or  $C_1$   $C_6$  alkyl optionally substituted with one to three halo substituents; and

n is an integer from 1 to 6 inclusively.

- 2. 8. (Cancelled)
- 9. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutical carrier, diluent, or excipient.
  - 10. 13. (Cancelled)
- 14. (Currently Amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:

$$R^1$$
 $Q$ 
 $R^5$ 
 $R^6$ 
 $R^4$ 
 $R^4$ 
 $R^4$ 
 $R^2$ 


or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is 
$$-C(R^{4c}) = \text{ or } -N = ;$$

 $R^1$  is  $C_1$ - $C_6$  alkyl, substituted  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_7$  cycloalkyl, substituted  $C_3$ - $C_7$  cycloalkyl, substituted  $C_3$ - $C_7$  cycloalkyl  $C_4$ - $C_5$  alkyl, substituted phenyl, substituted phenyl, heterocycle, or substituted heterocycle mono- di-, or tri-substituted phenyl wherein the substitutions are independently selected from halo,  $C_1$ - $C_2$  alkoxy, trifluoromethyl, trifluoromethoxy, and trifluoroethoxy;

R<sup>2</sup> is hydrogen or methyl; , C<sub>1</sub>-C<sub>3</sub> alkyl optionally substituted with one to three fluoro substituents, C<sub>3</sub>-C<sub>6</sub> cycloalkyl-C<sub>1</sub>-C<sub>3</sub> alkyl, or a group of formula II



 $R^3$  is hydrogen or  $C_1$ - $C_3$ -alkyl;

R<sup>4a</sup> and R<sup>4b</sup> are independently hydrogen, halo, or C<sub>1</sub>-C<sub>4</sub> alkyl optionally substituted with one to three fluoro substituents;

When X is  $-C(R^{4c})$ =,  $R^{4c}$  is hydrogen, halo, or  $C_4$ - $C_4$  alkyl optionally substituted with one to three fluoro substituents;

 $R^5 \ is \ hydrogen \ \underline{or} \ C_4\text{-}C_3\text{-}\underline{alkyl} \ \underline{optionally} \ \underline{substituted} \ \underline{with} \ \underline{one} \ to \ \underline{three} \ \underline{fluoro} \ \underline{substituents};$   $\underline{and}$ 

 $R^6$  is hydrogen or  $C_4$ - $C_3$ -alkyl optionally substituted with one to three fluoro substituents, provided that  $R^6$  may be  $C_4$ - $C_3$ -alkyl only when  $R^5$  is other than hydrogen;

 $R^{7}$  is hydrogen or  $C_{1}$   $C_{6}$  alkyl optionally substituted with one to three halo substituents; and

n is an integer from 1 to 6 inclusively.

15. (Original) The method according to Claim 14 wherein the mammal is a human.

16. - 28. (Cancelled)

## 29. (New) A compound of formula I:

$$R^1$$
 $Q$ 
 $R^5$ 
 $R^6$ 
 $Q$ 
 $R^6$ 
 $R^6$ 
 $R^4$ 
 $R^4$ 
 $R^4$ 
 $R^2$ 
 $R^2$ 

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is 
$$-C(H)= or -N=$$
;

R<sup>1</sup> is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

R<sup>4a</sup> and R<sup>4b</sup> are hydrogen;

R<sup>5</sup> is hydrogen; and

R<sup>6</sup> is hydrogen.

- 30. (New) A pharmaceutical composition comprising a compound according to Claim 29 and a pharmaceutical carrier, diluent, or excipient.
- 31. (New) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:

$$R^1$$
 $N$ 
 $X$ 
 $Q$ 
 $R^5$ 
 $R^6$ 
 $R^2$ 
 $R^4$ 
 $R^4$ 
 $R^2$ 

or a pharmaceutically acceptable acid addition salt thereof, where;

Q is oxygen or sulfur;

X is 
$$-C(H)= or -N=$$
;

R<sup>1</sup> is a substituted or unsubstituted heterocycle wherein the heterocycle is selected from the group consisting of pyridinyl and thiophenyl;

R<sup>2</sup> is hydrogen or methyl;

R<sup>3</sup> is hydrogen;

R<sup>4a</sup> and R<sup>4b</sup> are hydrogen;

R<sup>5</sup> is hydrogen; and

R<sup>6</sup> is hydrogen.

32. (New) The method according to Claim 31 wherein the mammal is a human.